Debra Heffernan
- Democratic
- Representative
- District 6
Primary
In 2000, the United States Federal Drug Administration ("FDA") first approved the Risk Evaluation and Mitigation Strategy ("REMS") for Mifeprex; and approved the generic version of Mifeprex, Mifepristone, in 2019. A regimen approved by the FDA in 2016 for Mifeprex and Mifepristone includes the use of Misoprostol. Under the REMS approved by the FDA, healthcare providers who wish to prescribe Mifepristone, Misoprostol, or Mifeprex must complete a Prescriber Agreement before ordering and dispensing the medication. Physicians assistants and advanced practiced registered nurses (APRNs) are healthcare providers who are eligible to prescribe these medications under the REMS. This bill allows physician assistants and advanced practice registered nurses to prescribe medication for the termination of pregnancy including Mifeprex, Mifepristone, and Misoprostol.
Signed by Governor
Passed By Senate. Votes: 14 YES 7 NO
Reported Out of Committee (Legislative Oversight & Sunset) in Senate with 3 Favorable
Re-Assigned to Legislative Oversight & Sunset Committee in Senate
Assigned to Health & Social Services Committee in Senate
Passed By House. Votes: 25 YES 15 NO 1 ABSENT
Reported Out of Committee (Health & Human Development) in House with 5 Favorable, 3 On Its Merits
Introduced and Assigned to Health & Human Development Committee in House
| Bill Text Versions | Format |
|---|---|
| Bill Text | PDF HTML |
| Document | Format |
|---|---|
| No related documents. |
Data on Open States is updated periodically throughout the day from the official website of the Delaware General Assembly.
If you notice any inconsistencies with these official sources, feel free to file an issue.